Genetic Susceptibility to Tobacco Carcinogenesis

References

• Pamell R W. Smoking and cancer [letter]. Lancet 1951; 1: 963
   Google Scholar
• Shopland D R, Eyre H J, Pechacek T F. Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States?. J Natl Cancer Inst 1991; 83: 1142–1148
   PubMed Web of Science ®Google Scholar
• Amos C I. Identifying gene-environment interactions in cancer etiology. Cancer Bull 1994; 46: 214–219
   Google Scholar
• Tokuhata G K, Lilienfeld A M. Familial aggregation of lung cancer in humans. J Natl Cancer Inst 1963; 30: 289–312
   PubMedGoogle Scholar
• Ooi W L, Elston R C, Chen V W, et al. Increased familial risk for lung cancer. J Natl Cancer Inst 1986; 76: 217–222
   PubMed Web of Science ®Google Scholar
• Sellers T A, Elston R C, Rothschild H. Familial risk of cancer among randomly selected cancer probands. Genet Epidemiol 1988; 5: 381–392
   PubMed Web of Science ®Google Scholar
• Sellers T A, Bailey-Wilson J E, Elston R C, et al. Evidence for mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst 1990; 82: 1272–1279
   PubMed Web of Science ®Google Scholar
• Yang P, Schwartz A G. Genetic epidemiology of lung cancer. II. Control segregation analysis of families of non-smoking lung cancer probands. Genet Epidemiol 1993; 10: 344
   Google Scholar
• Carmelli D, Swan G E, Robinerre D, et al. Genetic influence on smoking-a study of male twins. N Engl J Med 1992; 327: 829–833
   PubMed Web of Science ®Google Scholar
• Amos C I, Caporaso N E, Weston A. Host factors in lung cancer risk: a review of interdisciplinary studies. Cancer Epidemiol Bio-markers Prev 1992; 1: 505–513
   PubMed Web of Science ®Google Scholar
• Bishop J M. Molecular themes in oncogenesis. Cell 1991; 64: 235–248
   PubMed Web of Science ®Google Scholar
• Levine A J. The tumor suppressor genes. Annu Rev Biochem 1993; 62: 623–651
   PubMed Web of Science ®Google Scholar
• Sherr C J. Cancer cell cycles. Science 1996; 274: 1672–1677
   PubMed Web of Science ®Google Scholar
• Farber E. The multistep nature of cancer. Cancer Res 1984; 44: 4217–4223
   PubMed Web of Science ®Google Scholar
• Hoeijmakers J HJ. Human nucleotide excision repair syndromes. Molecular clues to unexpected intricacies. Eur J Cancer 1994; 30: 1912–1921
   Google Scholar
• Hagmar L, Brogger A, Hansteen I L, et al. Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 1994; 54: 2919–2922
   PubMed Web of Science ®Google Scholar
• Bonassi S, Abbondandolo A, Camurri L, et al. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. Cancer Genet Cytogenet 1995; 79: 133–135
   PubMed Web of Science ®Google Scholar
• Hsu T C, Johnston D A, Cherry L M, et al. Sensitivity to genotoxic events of bleomycin in humans: possible relationship to environmental carcinogens. Int J Cancer 1989; 43: 403–409
   PubMed Web of Science ®Google Scholar
• Spitz M R, Hsu T C, Wu X, et al. Mutagen sensitivity as a biologic marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 1995; 4: 99–103
   PubMed Web of Science ®Google Scholar
• Wu X, Delclos G L, Annegers F J, et al. A case-control study of wood-dust exposure, mutagen sensitivity, and lung-cancer risk. Cancer Epidemiol Biomarkers Prev 1995; 4: 583–588
   PubMed Web of Science ®Google Scholar
• Strom S S, Wu X F, Sigurdson A J, et al. Lung cancer, smoking patterns and mutagen sensitivity in Mexican-Americans. J Natl Cancer Inst Monogr 1995; 18: 29–33
   PubMedGoogle Scholar
• Spitz M R, Fueger J J, Beddingfield N A, et al. Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res 1989; 49: 4626–4628
   PubMed Web of Science ®Google Scholar
• Phillips D H. Fifty years of B[a]P. Nature 1983; 303: 468–472
   PubMed Web of Science ®Google Scholar
• Gelboin H V. Benzo[a]pyrene metabolism, activation, and carcinogenesis. Role and regulation of mixed function oxidases and related enzymes. Physiol Rev 1980; 60: 1107–1166
   PubMed Web of Science ®Google Scholar
• MacLeod M C, Tang M S. Interaction of benzo[a]pyrene-diol-ep-oxides with linear and supercoiled DNA. Cancer Res 1985; 45: 51–56
   PubMed Web of Science ®Google Scholar
• Jernstrom B, Graslund A. Covalent binding of benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide to DNA. Molecular structure, induced mutations and biological consequences. Biophys Chem 1994; 49: 185–199
   PubMed Web of Science ®Google Scholar
• Cosman M, de los Santos C, Fiala R, et al. Solution conformation of the major adducts between the carcinogen (+)-anti-benzo[a]-pyrene diol epoxide and DNA. Proc Natl Acad Sci USA 1992; 89: 1914–1918
   PubMed Web of Science ®Google Scholar
• Wei Q, Gu J, Cheng L, et al. Benzo[a]pyrene diol epoxide induced chromosomal aberrations in normal human lymphocytes. Cancer Res 1996; 56: 3975–3979
   PubMed Web of Science ®Google Scholar
• Wu X, Gu J, Amos C I, et al. A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung cancer cases and controls. Cancer 1998; 83: 1118–1127
   PubMed Web of Science ®Google Scholar
• Wei Q, Spitz M R, Gu J, et al. DNA repair capacity correlates with mutagen sensitivity in lymphoblastoid cell lines. Cancer Epidemiol Biomarkers Prev 1996; 5: 199–204
   PubMed Web of Science ®Google Scholar
• Wu X, Hsu T C, Annegers J F, et al. A case-control study of non-random distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer patients. Cancer Res 1995; 5: 557–561
   Google Scholar
• Wu X, Zhao Y, Kemp B L, et al. Chromosome 5 aberrations and genetic predisposition to lung cancer. Int J Cancer 1998; 79: 490–493
   PubMed Web of Science ®Google Scholar
• Roche J, Boldog F, Robinson M, et al. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 1996; 12: 1289–1297
   PubMed Web of Science ®Google Scholar
• Killary A M, Wolf M E, Giambemardi T A, et al. Definition of a tumor suppressor locu within human chromosome 3p21-p22. Proc Natl Acad Sci USA 1992; 89: 10877–10881
   PubMed Web of Science ®Google Scholar
• Sozzi G, Sard L, De Gregorio L, et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 1997; 57: 2121–2123
   PubMed Web of Science ®Google Scholar
• Wu X, Zhao Y, Horn S E, et al. Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. Cancer Res 1998; 90: 358–363
   Google Scholar
• Kellerman G, Luyten-Kellerman M, Shaw C R. Genetic variation of arylhydrocarbon hydroxylase in human lymphocytes. Am J Hum Genet 1973; 25: 327–331
   PubMed Web of Science ®Google Scholar
• Kouri R E, McKinney C E, Slomiany D J, et al. Positive correlation between high aryl hydrocarbon hydroxylase activity in primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 1982; 42: 5030–5037
   PubMed Web of Science ®Google Scholar
• Anttila S, Hirvonen A, Husgavel-F'ursiainen K, et al. Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histological type of lung cancer. Carcinogenesis 1994; 15: 1133–1135
   PubMed Web of Science ®Google Scholar
• Paigen B, Ward E, Steenland K, et al. Arylhydrocarbon hydroxylase in cultured lymphocytes of twins. Am J Hum Genet 1978; 30: 561–571
   PubMed Web of Science ®Google Scholar
• Bartsch H, Petruzzelli S, De Flora S, et al. Carcinogen metabolism in human lung tissues and the effect of tobacco smoking. Results from a case-control multicenter study on lung cancer patients. Environ Health Perspect 1992; 98: 119–124
   PubMed Web of Science ®Google Scholar
• Bartsch H, Hietanen E, Petruzzelli S, et al. Possible prognostic value of pulmonary AH-locus-linked enzymes in patients with tobacco-related lung cancer. Int J Cancer 1990; 46: 185–188
   PubMed Web of Science ®Google Scholar
• Nakachi K, Imai K, Hayashi S, et al. Genetic susceptibility to squarnous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1991; 51: 5177–5180
   PubMed Web of Science ®Google Scholar
• Jaiswal A K, Gonzalez F J, Nebert D W. Human P1–450 gene sequence and correlation of mRNA with genetic differences in benzo(a)pyrene metabolism. Nucleic Acids Res 1985; 13: 4503–4520
   PubMed Web of Science ®Google Scholar
• Kawajiri K, Nakachi K, Imai K, et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990; 263: 131–133
   PubMed Web of Science ®Google Scholar
• Hayashi S, Watanabe J, Nakachi K, et al. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem 1991; 110: 407–411
   PubMed Web of Science ®Google Scholar
• Cosma G, Crofts F, Taioli E, et al. Relationship between genotype and function of the human CYPl Al gene. J Toxico1 Environ Health 1993; 40: 309–316
   PubMed Web of Science ®Google Scholar
• Crofts F, Coma G N, Cunie D, et al. A novel CYP11 gene polymorphism in African-Americans. Carcinogenesis 1993; 14: 1729–1731
   PubMed Web of Science ®Google Scholar
• Kelsey K, Wiencke J K, Spitz M. A race-specific genetic polymorphism in the CYP1A1 gene is not associated with lung cancer in African Americans. Carcinogenesis 1994; 5: 1121–1124
   Google Scholar
• London S J, Daly A K, Fairbrother K S, et al. Lung cancer risk in African Americans in relation to a race-specific CYPlAl polymorphism. Cancer Res 1995; 55: 6035–6037
   PubMed Web of Science ®Google Scholar
• Shields P G, Caporaso N E, Falk R T, et al. Lung cancer, race, and CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev 1993; 2: 481–485
   PubMed Web of Science ®Google Scholar
• Hirvonen A, Husgafvel Pursiainen K, Anttila S, et al. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics 1992; 2: 259–263
   PubMedGoogle Scholar
• Tefre T, Ryberg D, Haugen A, et al. Human CYP1A1 (cytochrome P(1)450) gene. Lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1991; 1: 20–25
   PubMedGoogle Scholar
• Garcia-Closas M, Kelsey K T, Wiencke J K, et al. A case-control study of cytochrome P450 1 A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility. Cancer Causes Control 1997; 8: 544–553
   PubMed Web of Science ®Google Scholar
• Xu X, Kelsey K T, Wiencke J K, et al. Cytochrome P4501A1 Mspl polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1996; 5: 687–692
   PubMed Web of Science ®Google Scholar
• Nakachi K, Imai K, Hayashi S, et al. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993; 53: 2994–2999
   PubMed Web of Science ®Google Scholar
• Crofts F, Taioli E, Trachman J, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994; 15: 2961–2963
   PubMed Web of Science ®Google Scholar
• Cosma G, Crofts F, Cunie D, et al. Racial differences in restriction fragment length polymorphisms and messenger RNA inducibility of the human CYF1 A1 gene. Cancer Epidemiol Biomarkers Prev 1993; 2: 53–57
   PubMed Web of Science ®Google Scholar
• Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, et al. Point-mutational MspI and IIe-Val polymorphisms closely linked in the CYP1A1 gene. Lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1992; 1: 485–489
   PubMed Web of Science ®Google Scholar
• Mooney L A, Bell D A, Santella R M, et al. Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis 1997; 18: 503–509
   PubMed Web of Science ®Google Scholar
• Ayesh R, Idle S R, Ritchie J C, et al. Metabolic oxidation pheno-types as markers for susceptibility to lung cancer. Nature 1984; 312: 169–170
   PubMed Web of Science ®Google Scholar
• Crespi C L, Penman B W, Gelboin H V, et al. A tobacco smoke-derived nitrosamine, 4–(methylnitrosamino)-1–(3-pyridyl)-1-bu-tanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 1991; 12: 1197–1201
   PubMed Web of Science ®Google Scholar
• Heim M, Meyer U A. Genotyping of poor metabolisers of de-brisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529–532
   PubMed Web of Science ®Google Scholar
• Hirvonen A, Husgafvel-Pursiainen K, Anttila S, et al. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 1993; 3: 19–27
   PubMedGoogle Scholar
• Wolf C R, Smith C AD, Gough A C, et al. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992; 13: 1035–1038
   PubMed Web of Science ®Google Scholar
• Shaw G L, Falk R T, Deslauriers J, et al. Debrisoquine metabolism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995; 4: 41–48
   PubMed Web of Science ®Google Scholar
• Law M R, Hetzel M R, Idle J R. Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 1989; 59: 686–687
   PubMed Web of Science ®Google Scholar
• Caporaso N E, Shields P G, Landi M T, et al. The debrisoquine metabolic phenotype and DNA-based assays, implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Environ Health Perspect 1992; 98: 101–105
   PubMed Web of Science ®Google Scholar
• Bouchardy C, Benhamou S, Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 1996; 56: 251–253
   PubMed Web of Science ®Google Scholar
• Benhamou S, Bouchardy C, Paoletti C, et al. Effects of CYP2D6 activity and tobacco on larynx cancer risk. Cancer Epidemiol Biomarkers Prev 1996; 5: 683–686
   PubMed Web of Science ®Google Scholar
• Cholerton S, Arpanahi A, McCracken N, et al. Poor metabolizers of nicotine and CYP2D6 polymorphism. Lancet 1994; 343: 62–63
   PubMed Web of Science ®Google Scholar
• Guengerich F P, Kim D H, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4: 168–179
   PubMed Web of Science ®Google Scholar
• Koop D R. Oxidative and reductive metabolism by cytochrome P4502E1. FASEB J 1992; 6: 724–730
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inui Y, Yun C, et al. Cytochrome P4502E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992; 13: 1789–1794
   PubMed Web of Science ®Google Scholar
• Uematsu F, Ikawa S, Kikuchi H, et al. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer, possible relevance to low smoking exposure. Pharmacogenetics 1994; 4: 58–63
   PubMedGoogle Scholar
• Kato S, Shields P G, Caporaso N E, et al. Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol Biomarkers Prev 1994; 3: 515–518
   PubMed Web of Science ®Google Scholar
• Hayashi S I, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIEI gene. J Biochem 1991; 111: 559–565
   Google Scholar
• Watanabe J, Yang J P, Eguchi H, et al. An Rsa I polymorphism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population. Jpn J Cancer Res 1995; 86: 245–248
   PubMedGoogle Scholar
• Sugimura H, Hamada G S, Suzuki I, et al. CYP1A1 and CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro, Brazil. Pharmacogenetics 1995; 5: S145–148
   PubMedGoogle Scholar
• Stephens E A, Taylor J A, Kaplan N, et al. Ethnic variation in the CYP2E1 gene: Polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994; 4: 185–195
   PubMedGoogle Scholar
• Ingelman-Sundberg M, Johansson I, Persson I, et al. Genetic polymorphism of cytochromes P 450: Interethnic differences and relationship to incidence of lung cancer. Pharmacogenetics 1992; 2: 264–271
   PubMedGoogle Scholar
• Hirvonen A, Husgafvel-Fursiainen K, Anttila S, et al. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 1993; 14: 85–88
   PubMed Web of Science ®Google Scholar
• Persson I, Johansson I, Bergling H, et al. Genetic polymorphism of cytochrome P4502E1 in a Swedish population: Relationship to incidence of lung cancer. FEBS Lett 1993; 319: 207–211
   PubMed Web of Science ®Google Scholar
• Wu X, Shi H, Jiang H, et al. Association between chromosome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 1997; 18: 967–973
   PubMed Web of Science ®Google Scholar
• Seree E M, Villard P H, Re J L, et al. High inducibility of mouse renal CYP2E1 gene by tobacco smoke and its possible effect on DNA single strand breaks. Biochem Biophys Res Commun 1996; 219: 429–434
   PubMed Web of Science ®Google Scholar
• Ketterer B, Harris J M, Talaska G, et al. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 1992; 98: 87–94
   PubMed Web of Science ®Google Scholar
• Seidegard J, Guthenberg C, Pero R W, et al. The trans-stilbene oxide-active glutathione transferase in human mononuclear leucocytes is identical with the hepatic glutathione transferase mu. Biochem J 1987; 246: 783–785
   PubMed Web of Science ®Google Scholar
• Seidegard J, Vorachek W R, Pero R W, et al. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1988; 85: 7293–7297
   PubMed Web of Science ®Google Scholar
• Brockmoller J, Gross D, Kerb R, et al. Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class mu gene detected by polymerase chain reaction. Biochem Pharmacol 1992; 43: 647–650
   PubMed Web of Science ®Google Scholar
• Seidegard J, Pero R W, Markowitz M M, et al. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow-up study. Carcinogenesis 1990; 11: 33–36
   PubMed Web of Science ®Google Scholar
• Zhong S, Howie A F, Ketterer B, et al. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991; 12: 1533–1537
   PubMed Web of Science ®Google Scholar
• Kihara M, Noda K, Okamoto N. Increased risk of lung cancer in Japanese smokers with class mu glutathione S-transferase gene deficiency. Cancer Lett 1993; 71: 151–155
   PubMed Web of Science ®Google Scholar
• Nazar-Stewart V, Motulsky A G, Eaton D L, et al. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 1993; 53: 2313–2318
   PubMed Web of Science ®Google Scholar
• Heckbert S R, Weiss N S, Hornung S K, et al. Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst 1992; 84: 414–422
   PubMed Web of Science ®Google Scholar
• Brockmoller J, Kerb R, Drakoulis N, et al. Genotype and pheno-type of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res 1993; 53: 1004–1011
   PubMed Web of Science ®Google Scholar
• Hirvonen A, Husgafvel-Pursiainen K, Anttila S, et al. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 1993; 14: 1479–1481
   PubMed Web of Science ®Google Scholar
• Kihara M, Noda K. Lung cancer risk of GSTMl null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis 1994; 15: 415–418
   PubMed Web of Science ®Google Scholar
• Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 1992; 83: 866–870
   PubMedGoogle Scholar
• London S J, Daly A K, Cooper J, et al. Polymorphism of glutathione s-transferase ml and lung cancer risk among African-Amencans and Caucasians in Los Angeles county, California. J Natl Cancer Inst 1995; 87: 1246–1253
   PubMed Web of Science ®Google Scholar
• Garcia-Closas M, Kelsey K T, Wiencke J K, et al. Nutrient intake as a modifier of the association between lung cancer and glutathi-one-S-transferase mu deletion. Proc Am Assoc Cancer Res 1995; 36: A1675
   Google Scholar
• Mc Williams J E, Sanderson B J, Hanis E L, et al. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1991; 4: 589–594
   Google Scholar
• Meyer D J, Coles B, Pemble S E, et al. Theta, a new class of glutathione transferases purified from rat and man. Biochem J 1991; 274: 409–414
   PubMed Web of Science ®Google Scholar
• Pemble S, Schroeder K R, Spencer S R, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994; 300: 271–276
   PubMed Web of Science ®Google Scholar
• el-Zin R, Conforti-Froes N, Au W W. Interactions between genetic predisposition and environmental toxicants for development of lung cancer. Environ Mol Mutagen 1997; 30: 196–204
   PubMed Web of Science ®Google Scholar
• Kelsey K T, Spitz M R, Zuo Z F, et al. Polymorphisms in the glutathione S-transferase class mu and theta genes interact and increase susceptibility to lung cancer in minority populations (Texas, United States). Cancer Causes Control 1997; 8: 554–559
   PubMed Web of Science ®Google Scholar
• Jourenkova N, Reinikainen M, Benhamou S, et al. Lung cancer risk in relation to glutathione S-transferase (GSTM1 and GSTT1) genotypes and tobacco exposure. Proc Am Assoc Cancer Res 1997; 38: A1433
   Google Scholar
• Saarikoski S T, Voho A, Reinikainen M, et al. Combined effects of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer 1998; 77: 516–521
   PubMed Web of Science ®Google Scholar
• Alexandrie A K, Sundberg M I, Seidegard J, et al. Genetic susceptibility to lung cancer with special emphasis on CYPlA1 and GSTM 1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 1994; 15: 1785–1790
   PubMed Web of Science ®Google Scholar
• Blum M, Demiem A, Grant D M, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991; 88: 5237–5241
   PubMed Web of Science ®Google Scholar
• Deguchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 1992; 267: 18140–18147
   PubMed Web of Science ®Google Scholar
• Bell D A, Taylor J A, Butler M A, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Amencans. Carcinogenesis 1993; 14: 1689–1692
   PubMed Web of Science ®Google Scholar
• Vineis P, Bartsch H, Caporaso N, et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994; 369: 154–156
   PubMed Web of Science ®Google Scholar
• Wu X, Liu J H, Trizna Z, et al. The association of N-acetylator, mutagen sensitivity and lung cancer risk. Proc Am Assoc Cancer Res 1996; 37: 263
   Google Scholar
• Knowles M A, Shaw M E, Proctor A J. Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 1993; 8: 1357–1364
   PubMed Web of Science ®Google Scholar
• Kadlubar F F, Badawi A F. Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis. Toxicol Lett 1995; 82–83: s627–s632
   PubMed Web of Science ®Google Scholar
• Bell D A, Badawi A F, Lang N P, et al. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: Association of NAT110 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995; 55: 5226–5229
   PubMed Web of Science ®Google Scholar
• Wu X, Hsu T C, Cao S, et al. Deletion in poly(ADP-ribose)poly-merase pseudogene and lung cancer risk. Carcinogenesis 1998; 19: 93–98
   PubMed Web of Science ®Google Scholar
• Cleaver J E. Kraemer K Xeroderma pigmentosum. The Metabolic Basis of Inherited Diseases II, C R Scriver, A L Beaudet, W S Sly, D Valle. McGraw-Hill, New York 1989; 2949–2971
   Google Scholar
• Friedberg E C. DNA Repair. WH Freedman and Company, New York 1985
   Google Scholar
• Tang M S, Pierce J R, Doisy R P, et al. Differences and similarities in the repair of two benzo[a]pyrene diol epoxide isomers induced DNA adducts by uvrA, uvrB, and uvrC gene products. Biochemistry 1992; 31: 8429–8436
   PubMed Web of Science ®Google Scholar
• Sancer A. Mechanisms of DNA excision repair. Science 1994; 266: 1954–1956
   PubMed Web of Science ®Google Scholar
• Athas W F, Hedayati M, Matanoski G M, et al. Development and field-test validation of an assay for DNA repair in circulating human lymphocytes. Cancer Res 1991; 51: 5786–5793
   PubMed Web of Science ®Google Scholar
• Wei Q, Matanoski G M, Farmer E R, et al. DNA repair and susceptibility to skin cancer. Am J Epidemiol 1994; 140: 589–607
   Google Scholar
• Wei Q, Matanoski G M, Farmer E R, et al. DNA repair related to multiple skin cancers and drug use. Cancer Res 1994; 54: 437–440
   PubMed Web of Science ®Google Scholar
• Wei Q, Cheng L, Hong W K, et al. Reduced DNA repair capacity in lung cancer patients. Cancer Res 1996; 56: 4103–4107
   PubMed Web of Science ®Google Scholar
• Li D, Wang M, Cheng L, et al. In vitro induction of benzo[a]pyr-ene diol epoxide-induced DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer. Cancer Res 1996; 56: 3638–3641
   PubMed Web of Science ®Google Scholar
• Reddy M V, Randerath K. Nuclease PI-mediated enhancement of sensitivity of 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 1986; 7: 1543–1551
   PubMed Web of Science ®Google Scholar
• Watson W P. Postradiolabeling for detection of DNA damage. Mutagenesis 1987; 2: 319–331
   PubMed Web of Science ®Google Scholar
• Phillips D H, Hewer A, Grover P L. Aromatic DNA adducts in human bone marrow and peripheral blood leukocytes. Carcinogenesis 1986; 7: 2071–2075
   PubMed Web of Science ®Google Scholar
• Phillips D H, Hewer A, Martin C N, et al. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 1988; 336: 790–792
   PubMed Web of Science ®Google Scholar
• Reddy M V, Gupta R C, Randerath E, et al. 32P-postlabeling test for covalent DNA binding of chemicals in vivo: application to a variety of aromatic carcinogenes and methylating agents. Car-cinogenesis 1984; 5: 231–243
   PubMed Web of Science ®Google Scholar
• van Schooten F J, Hillebrand M J, van Leeuwen F E, et al. Poly-cyclic aromatic hydrocarbon-DNA adducts in white blood cells from lung cancer patients: no correlation with adduct levels in the lung. Carcinogenesis 1992; 13: 987–993
   PubMed Web of Science ®Google Scholar
• Savela K, Hemminki K. DNA adducts in lymphocytes and gran-ulocytes of smokers and nonsmokers detected by the 32P-post-labelling assay. Carcinogenesis 1991; 1: 503–508
   Google Scholar
• Gupta R C, Earley K, Sharma S. Use of human peripheral blood lymphocytes to measure DNA binding capacity of chemical carcinogens. Proc Natl Acad Sci USA 1988; 85: 3513–3517
   PubMed Web of Science ®Google Scholar
• Everson R B, Randerath E, Santella R M, et al. Detection of smoking-related covalent DNA adducts in human placenta. Science 1986; 231: 54–59
   PubMed Web of Science ®Google Scholar
• Geneste O, Camus A M, Castegaro M, et al. Comparison of pulmonary DNA adduct levels, measured by 32P-post-labelling and aryl hydrocarbon hydroxylase activity in lung parenchyma of smokers and ex-smokers. Carcinogenesis 1991; 12: 1301–1305
   PubMed Web of Science ®Google Scholar
• Barret J M, Calsou P, Salles B. Deficient nucleotide excision repair activity in protein extracts from normal human lymphocytes. Carcinogenesis 1995; 7: 1611–1616
   Google Scholar
• Krolewski B, Little J B, Reynolds R J. Effect of duration of exposure to benzo[a]pyrene diol-epoxide on neoplastic transformation, mutagenesis, cytotoxicity and total covalent binding to DNA of rodent cells. Teratog Carcinog Mutagen 1988; 8: 127–136
   PubMedGoogle Scholar
• Wei Q, Spitz M E. The role of DNA repair capacity in susceptibility to lung cancer. Cancer Metastasis Rev 1997; 16: 295–307
   PubMed Web of Science ®Google Scholar